Log In
Print
BCIQ
Print
Print this Print this
 

viagenpumatucel-L (HS-110)

  Manage Alerts
Collapse Summary General Information
Company Heat Biologics Inc.
DescriptionVaccine comprising lung cancer cells engineered using ImPACT technology to secrete antigens bound to a heat shock 90 kDa protein beta 1 (Hsp90B1; GP96; GRP94) adjuvant
Molecular Target Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC) in patients who have failed >=1 prior lines of therapy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today